A Phase 1 study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor in patients with refractory solid tumor malignancies and lymphomas

PURPOSE: To determine the maximum tolerated dose (MTD), toxicities, and pharmacokinetic-pharmacodynamic profile of the heat shock protein 90 (Hsp90) inhibitor PF-04929113 (SNX-5422) in patients with advanced solid tumors and lymphomas. METHODS: This was a single institution, phase I, dose-escalation...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Rajan, Arun, Kelly, Ronan J., Trepel, Jane B., Kim, Yeong Sang, Alarcon, Sylvia V., Kummar, Shivaani, Gutierrez, Martin, Crandon, Sonja, Zein, Wadih M., Jain, Lokesh, Mannargudi, Baskar, Figg, William D., Houk, Brett E., Shnaidman, Michael, Brega, Nicoletta, Giaccone, Giuseppe
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3207004/
https://ncbi.nlm.nih.gov/pubmed/21908572
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-0821
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki